WuXi Advanced Therapies' 55,000 square-foot commercial non-viral cell therapy manufacturing site, located in Philadelphia (via PR Newswire)
WuXi AppTec subsidiary to manufacture Iovance’s solid tumor TIL therapy in US
WuXi Advanced Therapies (ATU) will manufacture Iovance’s recently approved Amtagvi for advanced melanoma, which was heralded as the first
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
